Anti-angiogenic therapies in prostate cancer

Expert Opinion on Biological Therapy

Volumn 13, Issue 1, 2013, Pages 1-5

  Martínez Jabaloyas, José María ^a   March Villalba, José Antonio ^a   Navarro García, María Mercedes ^a   Dasi, Francisco ^a,b  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Angiogenesis; Anti angiogenic therapies; Prostate cancer; Review

Indexed keywords

AFLIBERCEPT; ANGIOSTATIN; BEVACIZUMAB; CEDIRANIB; DASATINIB; DOCETAXEL; ENDOSTATIN; ESTRAMUSTINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; INTERLEUKIN 12; PAZOPANIB; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE; SORAFENIB; SUNITINIB; THALIDOMIDE; THROMBOSPONDIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E;

ANDROGEN DEPRIVATION THERAPY; ANTIANGIOGENIC THERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL MIGRATION; CELL PROLIFERATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); HUMAN; METASTASIS; OXYGEN SUPPLY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; EVIDENCE-BASED MEDICINE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84870937163     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.733366     Document Type: Review

References (15)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics 2012. CA Cancer J Clin 2012;62:10-29
2. Attard G, de Bono JS. Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients. Clin Cancer Res 2011;17:3867-75
3. Hwang C, Heath EI. Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol 2010;3:26
4. Aragon-Ching JB, Madan RA, Dahit WL. Angiogenesis inhibition in prostate cancer: Current uses and future promises. J Oncol 2010;Article ID 361836:7 pages. This article is a comprehensive review on anti-angiogenic inhibitors in PCa treatment with special remarks on challenges and future prospects.
5. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74
6. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182-6
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64
8. Chung A, Lee J, Ferrara N. Targeting the tumor vasculature: Insights from physiological angiogenesis. Nat Rev Cancer 2010;10:505-14
9. Jimenez JA, Kao C, Raikwar S, Gardner TA. Current status of anti-angiogenesis therapy for prostate cancer. Urol Oncol 2006;24:260-8
10. Shojaei F. Anti-angiogenesis therapy in cancer: Current challenges and future perspectives. Cancer Lett 2012;320:130-7
11. Ferrara N. From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials -an interview with Napoleone Ferrara by Domenico Ribatti. Int J Dev Biol 2011;55:383-8
12. Bianchini D, Zivi A, Sandhu A, de Bono JS. Horizon scanning for novel therapeutics for the treatment of prostate cancer. Expert Opin Investig Drugs 2010;19:1487-502
13. Osanto S, Van Poppel H. Emerging new therapies for advanced prostate cancer. Ther Adv Urol 2012;4:3-12
14. Roukos DH, Tzakos A, Zografos G. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 2009;9:1413-16
15. Ribatti D. Antiangiogenic therapy accelerates tumor metastasis. Leuk Res 2011;35:24-6